4.7 Article

Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity

Journal

BRAIN
Volume 145, Issue 10, Pages 3500-3508

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/awac185

Keywords

pre-symptomatic; phenoconversion; prodromal disease

Funding

  1. Muscular Dystrophy Association [4365, 172123]
  2. ALS Association [2015]
  3. National Institutes of Health [R01 NS105479, U54 NS090291]
  4. ALS Recovery Fund
  5. Kimmelman Estate
  6. Swedish Brain Foundation [2016-0303, 2018-0310, 2020-0353]
  7. Swedish Research Council [2012-3167, 2017-03100]
  8. Knut and Alice Wallenberg Foundation [2012.0091, 2014.0305, 2020.0232]
  9. Ulla-Carin Lindquist Foundation, and Neuroforbundet
  10. ALS Association
  11. Swedish Research Council [2017-03100] Funding Source: Swedish Research Council

Ask authors/readers for more resources

Amyotrophic lateral sclerosis (ALS) may evolve along a continuum and have a prodromal phase of mild motor impairment (MMI) that is often missed. Through studying pre-symptomatic gene mutation carriers, it is observed that mild motor impairment is an observable state that precedes clinically manifest ALS, providing potential for diagnosis and early therapeutic intervention.
Amyotrophic lateral sclerosis, when viewed as a biological entity rather than a clinical syndrome, probably evolves along a continuum, with the initial clinically silent phase eventually evolving into clinically manifest amyotrophic lateral sclerosis. Since motor neuron degeneration is incremental and cumulative over time, it stands to reason that the clinical syndrome of amyotrophic lateral sclerosis is probably preceded by a prodromal state characterized by minor motor abnormalities that are initially insufficient to permit a diagnosis of amyotrophic lateral sclerosis. This prodromal period, however, is usually missed, given the invariably long delays between symptom onset and diagnostic evaluation. The Pre-Symptomatic Familial ALS Study, a cohort study of pre-symptomatic gene mutation carriers, offers a unique opportunity to observe what is typically unseen. Here we describe the clinical characterization of 20 pre-symptomatic mutation carriers (in SOD1, FUS and C9orf72) whose phenoconversion to clinically manifest disease has been prospectively studied. In so doing, we observed a prodromal phase of mild motor impairment in 11 of 20 phenoconverters. Among the n = 12 SOD1 A4V mutation carriers, phenoconversion was characterized by abrupt onset of weakness, with a short (1-3.5 months) prodromal period observable in a small minority (n = 3); the observable prodrome invariably involved the lower motor neuron axis. By contrast, in all n = 3 SOD1 I113T mutation carriers, diffuse lower motor neuron and upper motor neuron signs evolved insidiously during a prodromal period that extended over a period of many years; prodromal manifestations eventually coalesced into a clinical syndrome that is recognizable as amyotrophic lateral sclerosis. Similarly, in all n = 3 C9orf72 hexanucleotide repeat expansion mutation carriers, focal or multifocal manifestations of disease evolved gradually over a prodromal period of 1-2 years. Clinically manifest ALS also emerged following a prodromal period of mild motor impairment, lasting >4 years and similar to 9 months, respectively, in n = 2 with other gene mutations (SOD1 L106V and FUS c.521del6). On the basis of this empirical evidence, we conclude that mild motor impairment is an observable state that precedes clinically manifest disease in three of the most common genetic forms of amyotrophic lateral sclerosis (SOD1, FUS, C9orf72), and perhaps in all genetic amyotrophic lateral sclerosis; we also propose that this might be true of non-genetic amyotrophic lateral sclerosis. As a diagnostic label, mild motor impairment provides the language to describe the indeterminate (and sometimes intermediate) transition between the unaffected state and clinically manifest amyotrophic lateral sclerosis. Recognizing mild motor impairment as a distinct clinical entity should generate fresh urgency for developing biomarkers reflecting the earliest events in the degenerative cascade, with potential to reduce the diagnostic delay and to permit earlier therapeutic intervention. Having observed ALS phenoconversion in 20 pre-symptomatic gene mutation carriers, Benatar et al. conclude that a prodromal period of mild motor impairment (MMI) precedes many (if not most) forms of ALS. They highlight the implications for reducing diagnostic delay and for early therapeutic intervention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available